Stock Pulse
Cardinal Health (CAH) will be the key U.S. distributor for Telix Pharmaceuticals' new prostate cancer imaging agent, Gozellix, expanding their existing partnership and strengthening CAH's position in the radiopharmaceutical distribution market [6], [7], [9]. This deal leverages CAH's extensive network and expands their product portfolio [6]. CAH is considered a strong value stock with a Zacks Rank #3 (Hold) and attractive valuation ratios [2]. Upcoming Q1 2025 earnings are expected to show modest year-over-year growth [3], [4]. While CAH's ROCE has improved significantly [5], high reliance on short-term funding requires further investigation [5]. Stock performance has been relatively stable [4], and a director recently acquired shares [11].